WO2008157473A1 - Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens - Google Patents
Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens Download PDFInfo
- Publication number
- WO2008157473A1 WO2008157473A1 PCT/US2008/067088 US2008067088W WO2008157473A1 WO 2008157473 A1 WO2008157473 A1 WO 2008157473A1 US 2008067088 W US2008067088 W US 2008067088W WO 2008157473 A1 WO2008157473 A1 WO 2008157473A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonist
- antigen
- cancer
- regimen
- tnf
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title claims abstract description 297
- 102000014150 Interferons Human genes 0.000 title claims abstract description 55
- 108010050904 Interferons Proteins 0.000 title claims abstract description 48
- 238000011285 therapeutic regimen Methods 0.000 title claims description 11
- 230000001988 toxicity Effects 0.000 title abstract description 37
- 231100000419 toxicity Toxicity 0.000 title abstract description 37
- 229940047124 interferons Drugs 0.000 title description 13
- 238000009097 single-agent therapy Methods 0.000 claims abstract description 49
- 231100000304 hepatotoxicity Toxicity 0.000 claims abstract description 44
- 229940079322 interferon Drugs 0.000 claims abstract description 42
- 230000007056 liver toxicity Effects 0.000 claims abstract description 42
- 230000001976 improved effect Effects 0.000 claims abstract description 11
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims abstract description 10
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims abstract 7
- 101150013553 CD40 gene Proteins 0.000 claims abstract 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims description 222
- 102000036639 antigens Human genes 0.000 claims description 216
- 108091007433 antigens Proteins 0.000 claims description 215
- 206010028980 Neoplasm Diseases 0.000 claims description 194
- 102000002689 Toll-like receptor Human genes 0.000 claims description 172
- 108020000411 Toll-like receptor Proteins 0.000 claims description 172
- 210000004027 cell Anatomy 0.000 claims description 104
- 201000011510 cancer Diseases 0.000 claims description 56
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 47
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 47
- 229940123189 CD40 agonist Drugs 0.000 claims description 40
- 230000028993 immune response Effects 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 33
- 208000015181 infectious disease Diseases 0.000 claims description 27
- 230000015654 memory Effects 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 102100032937 CD40 ligand Human genes 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 210000004185 liver Anatomy 0.000 claims description 19
- 108010029697 CD40 Ligand Proteins 0.000 claims description 17
- 230000003612 virological effect Effects 0.000 claims description 17
- 230000001681 protective effect Effects 0.000 claims description 16
- 206010025323 Lymphomas Diseases 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 15
- 230000001270 agonistic effect Effects 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 12
- 230000024932 T cell mediated immunity Effects 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 10
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 244000045947 parasite Species 0.000 claims description 9
- 230000005867 T cell response Effects 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 241000709661 Enterovirus Species 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 5
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 5
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 241000194017 Streptococcus Species 0.000 claims description 5
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 5
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 241000186216 Corynebacterium Species 0.000 claims description 4
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 4
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 4
- 241001631646 Papillomaviridae Species 0.000 claims description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 4
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 3
- 241000606161 Chlamydia Species 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 3
- 241000222722 Leishmania <genus> Species 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000711386 Mumps virus Species 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 3
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 3
- 241000223996 Toxoplasma Species 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 241000701386 African swine fever virus Species 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241000223203 Coccidioides Species 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241001466953 Echovirus Species 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000244206 Nematoda Species 0.000 claims description 2
- 241000187654 Nocardia Species 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 241000606860 Pasteurella Species 0.000 claims description 2
- 241000233870 Pneumocystis Species 0.000 claims description 2
- 241001505332 Polyomavirus sp. Species 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000607720 Serratia Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000000317 pneumocystosis Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 241000223836 Babesia Species 0.000 claims 1
- 241000589968 Borrelia Species 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 241000588698 Erwinia Species 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 241000863392 Pelobacter Species 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 241000242594 Platyhelminthes Species 0.000 claims 1
- 241000223104 Trypanosoma Species 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 201000008680 babesiosis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 41
- 238000002560 therapeutic procedure Methods 0.000 abstract description 16
- 241000699670 Mus sp. Species 0.000 description 95
- -1 4- IBBL Proteins 0.000 description 91
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 80
- 102100040247 Tumor necrosis factor Human genes 0.000 description 74
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 65
- 210000001744 T-lymphocyte Anatomy 0.000 description 62
- 239000002671 adjuvant Substances 0.000 description 60
- 230000003308 immunostimulating effect Effects 0.000 description 56
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 52
- 239000000203 mixture Substances 0.000 description 50
- 238000002474 experimental method Methods 0.000 description 46
- 230000001225 therapeutic effect Effects 0.000 description 44
- 238000011282 treatment Methods 0.000 description 39
- 150000001875 compounds Chemical class 0.000 description 37
- 210000004072 lung Anatomy 0.000 description 31
- 229940124669 imidazoquinoline Drugs 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 238000001727 in vivo Methods 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- 238000002255 vaccination Methods 0.000 description 24
- 229960005486 vaccine Drugs 0.000 description 24
- 238000002649 immunization Methods 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 230000004044 response Effects 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- 239000012636 effector Substances 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000011260 co-administration Methods 0.000 description 15
- 230000036039 immunity Effects 0.000 description 14
- 206010061289 metastatic neoplasm Diseases 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 230000004913 activation Effects 0.000 description 12
- 230000001461 cytolytic effect Effects 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 230000001394 metastastic effect Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 206010028851 Necrosis Diseases 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 102100032912 CD44 antigen Human genes 0.000 description 9
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 9
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 9
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000012190 activator Substances 0.000 description 9
- 230000008484 agonism Effects 0.000 description 9
- 230000001363 autoimmune Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000016396 cytokine production Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 7
- 101150029707 ERBB2 gene Proteins 0.000 description 7
- 206010019837 Hepatocellular injury Diseases 0.000 description 7
- 108010054267 Interferon Receptors Proteins 0.000 description 7
- 206010027458 Metastases to lung Diseases 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 7
- 238000002784 cytotoxicity assay Methods 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000015788 innate immune response Effects 0.000 description 7
- 230000021633 leukocyte mediated immunity Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 102100029974 GTPase HRas Human genes 0.000 description 6
- 101710091881 GTPase HRas Proteins 0.000 description 6
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 6
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 230000033289 adaptive immune response Effects 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 210000003071 memory t lymphocyte Anatomy 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 102000007499 CD27 Ligand Human genes 0.000 description 5
- 108010046080 CD27 Ligand Proteins 0.000 description 5
- 102100025221 CD70 antigen Human genes 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 108090000340 Transaminases Proteins 0.000 description 5
- 102000003929 Transaminases Human genes 0.000 description 5
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 5
- 230000004721 adaptive immunity Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000001112 coagulating effect Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000010231 histologic analysis Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 208000021039 metastatic melanoma Diseases 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 4
- 102000009410 Chemokine receptor Human genes 0.000 description 4
- 108050000299 Chemokine receptor Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 125000003368 amide group Chemical class 0.000 description 4
- 125000003118 aryl group Chemical class 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 231100000437 hepatocellular injury Toxicity 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 238000012933 kinetic analysis Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 108010017987 CD30 Ligand Proteins 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 229910019142 PO4 Chemical class 0.000 description 3
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 208000003152 Yellow Fever Diseases 0.000 description 3
- 238000011292 agonist therapy Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 108010048032 cyclophilin B Proteins 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Chemical class 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 108010063916 CD40 Antigens Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 2
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150064015 FAS gene Proteins 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 description 2
- 208000004729 Feline Leukemia Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101150031823 HSP70 gene Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 229930191564 Monensin Natural products 0.000 description 2
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 2
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 102000018795 RELT Human genes 0.000 description 2
- 108010052562 RELT Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical class OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000014564 chemokine production Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000011220 combination immunotherapy Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 101150052825 dnaK gene Proteins 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 229960005358 monensin Drugs 0.000 description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 241000743339 Agrostis Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000743857 Anthoxanthum Species 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000256836 Apis Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000508787 Arrhenatherum Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241001367053 Autographa gamma Species 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000219429 Betula Species 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000238658 Blattella Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 241000723437 Chamaecyparis Species 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000588881 Chromobacterium Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000218692 Cryptomeria Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000723198 Cupressus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 241000209210 Dactylis Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000744855 Holcus Species 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222740 Leishmania braziliensis Species 0.000 description 1
- 241000222736 Leishmania tropica Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001268782 Paspalum dilatatum Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000745991 Phalaris Species 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000209048 Poa Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 239000012651 immune agonist Substances 0.000 description 1
- 229940044680 immune agonist Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000002809 long lived plasma cell Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000724775 unclassified viruses Species 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
Definitions
- the invention generally relates to methods of alleviating toxicity, especially liver toxicity observed upon administration of TNF/TNF-R super family agonists, most especially CD40 agonists, by further administering in a therapeutic or immune adjuvant regimen that comprises the administration of a TNF/TNF-R agonist that causes liver toxicity when used as a monotherapy an amount of at least one type 1 interferon and/or toll-like receptor (TLR) agonist sufficient to prevent or alleviate said toxicity, especially liver toxicity.
- TLR toll-like receptor
- the addition of the type 1 interferon and/or TLR agonist allows for the TNF-R agonist to be administered at higher dosages thereby enhancing efficacy.
- These therapeutic regimens include by way of example use of these immune agonist and/or cytokine immunostimulatory combinations for treating various chronic diseases including cancer, infectious diseases, autoimmune diseases, allergic and inflammatory diseases.
- Alum is salts of aluminum hydroxide and phosphate and primarily elicits humoral-mediated immune responses. This adjuvant was first employed in 1926 and was effectively grandfathered in when the FDA first assumed new drug approval authority in 1938. Alum is the only FDA approved adjuvant, and is a component of a number of our commonly used vaccines, like tentanus toxoid.
- TLRs are type 1 membrane proteins that are expressed on hematopoietic and non-hematopoietic cells. Currently, there are 11 members in the TLR family.
- PAMP pathogen-associated molecular patterns
- Typical PAMPS include LPS, DNA (CpG), lipoproteins, ssRNA, and glycolipids.
- CD 154 or CD40L the ligand for CD40 (CD40L, gp39) is a 32-39 kD member of the Tumor Necrosis Factor Family, which includes TNF- ⁇ , lymphotoxin, FasL, CD30L, CD27L, 4- IBBL, and OX-40L.
- CD4 T-cells are the predominant cell type responsible for CDl 54 expression. Expression of CDl 54 on CD8 + T-cells, eosinophils, mast cells and basophils, NK cells, and DCs has also been described.
- the receptor for CDl 54, CD40 is a member of the tumor necrosis factor receptor (TNF-R) superfamily that includes TNF-RI (p55), TNF-RII (p75) 5 p75 neurotrophin receptor, fas, CD30, CD27, 4- IBB, and OX-40.
- TNF-R tumor necrosis factor receptor
- CD40 triggering of DCs is the change in the turnover of peptide- MHCII.
- Lanzavecchia has shown using LPS and we have shown using, that maturation of DCs with a CD40 agonist facilitates the accumulation of MHCII-peptide complexes on the surface of DCs.
- CD40 agonists to elicit CMI in the absence of CD4 " T cells generated substantial enthusiasm to use CD40 agonists as adjuvants for cancer vaccines.
- a series of studies by Glennie and co-workers showed that one can achieve tumor regression of CD40 + lymphoma using QCD40, but the doses of anti-CD40 were very high (250ug/day, days 2-5), and oddly, the tumor inoculum needed for immunization was very high (5xl0 7 /mouse). Nonetheless, clinical remission of these CD40 "1" lymphoma was impressive. Less impressive were studies on hematopoietic tumors which were CD40 " .
- CD40 + lymphomas and leukemias were due to direct effects of CD40 agonists on the tumor.
- CD40 agonists may also enhance their APC activities, and at the same time enhance their apoptosis.
- CD40 agonists alone or TLR agonists alone could elicit effective therapeutic on AdSElA expressing (CD40-) tumors in vivo (tumor type not described).
- TLR agonists AdSElA expressing tumors in vivo (tumor type not described).
- Murphy and co-workers have shown that only the combination of an agonist anti-CD40 and IL-2, but neither agent administered alone, induced complete regression of metastatic tumor and specific immunity to subsequent rechallenge in the majority of treated mice, At this time efficacy with CD40 agonists alone is unpredictable.
- CD40 expression on the tumor is important, if tumor burden is important, if CD40 alone is adequate and if there is a distinctive difference in the efficacy of CD40 agonist therapy in liquid or solid tumors.
- CD40 is a reasonable target for inducing heightened CMI responses for the purposes of tumor protection, yet the data in the literature suggested that it was not applicable in a wide range of tumors.
- Those skilled in the art including the inventors have worked intensively to try to develop a general method to enhance protective tumor immunity using anti-CD40 antibody as a monotherapy, and failed.
- This invention relates to improved therapies involving the administration of immune adjuvants comprising the combination of (i) at least one TNF-R agonist, preferably an CD40 agonist comprised in a dosage that in clinical studies when used as a monotherapy elicits liver toxicity in some subjects (ii) an amount of at least one type 1 interferon and/or at least one
- TLR agonist at a dosage which is statistically effective to reduce or eliminate the liver toxicity of said TNF-R agonist dosage if administered as a monotherapy and (iii) optionally an antigen against which a cellular immune response is desirably elicited, e.g., a microbial, viral or tumor antigen.
- an antigen against which a cellular immune response is desirably elicited e.g., a microbial, viral or tumor antigen.
- the present invention further relates to the use of such therapies and compositions for use therein as immune adjuvants and for treating conditions wherein T cell immunity is desirably enhanced but without an undesirable elicitation of liver toxicity.
- synergistic adjuvants comprising a TLR agonist and a CD40 agonist or
- This invention is an extension thereof as it relates to the discovery that type 1 interferons and/or TLR agonists can be used to reduce or eliminate the toxic side effects of TNF-
- R agonist therapeutic regimens The subject therapeutic regimen may be administered to a host in need of such treatment as a means of :
- the present regimen is both safe and effective, i.e., it does not appreciably result in any toxicity to the liver.
- the present invention provides for enhanced efficacy as the TNF-R agonist, e.g., a CD40 agonist may be used at higher dosages, e.g. 2-fold to even 10-fold higher than present therapeutic regimens, but without liver toxicity. This will enhance the efficacy thereof against target cells, e.g. virally infected or tumor cells.
- the present invention in particular reveals the impact of combination therapy with that of monotherapy on the antigen-specific immune responses to melanoma at the cellular and molecular levels and on toxicity.
- the studies contained in the examples infra demonstrate the profound utility of CD40 and TLR agonists when combined in an adjuvant platform in a murine model of cancer.
- the data show that vaccination induces extremely high frequencies of primary and memory self-reactive CD8 + T cells that infiltrate metastatic target organs and control tumor growth.
- Combination therapy also reduces the ratio of regulatory T cells (T regs ) to CD8 + T cells at the tumor site and allows persistent effector CD8 + T-cell function.
- these immune adjuvant combinations which optionally may further include an antigen may be used in treating any disease or condition wherein the above-identified enhanced cellular immune responses are therapeutically desirable, especially infectious diseases, proliferative disorders such as cancer, allergy, autoimmune disorders, inflammatory disorders, and other chronic diseases wherein enhanced cellular immunity is a desired therapeutic outcome.
- Preferred applications of the invention include especially the treatment of infectious disorders such as HIV infection and cancer.
- FIGURE 1 This Figure contains experiments that show that concomitant signaling through CD40 and TLR7 drives the expansion of self-antigen specific CD8+ T cells with enhanced cytolytic activity.
- C57BL/6 mice were immunized intravenously with 100 ⁇ g of the tumor-associated antigen V, 100 ⁇ g CD40 FGK45, and 100 ⁇ g S-27609 in combinations as indicated. Seven days later, mice were bled and cells were restimulated in vitro with TRP2(igo-] 8S ) to assess the ability to produce IFN and translocate CD 107a as described in "Methods.” Lymphocytes were identified by forward and side scatter and subsequently gated on all CD8 ⁇ events.
- FIGURE 2 This figure contains experiments which show that in contrast to
- CD40 agonist monotherapy CD40 agonist/TLR6 agonist therapy rescues T cell function .
- mice were immunized with 100 ⁇ g each of V peptide, CD40, and S-27609 in combinations as indicated. Memory CD8 + functionality was assessed 65 days later.
- A Representative dot plots of IFN secretion by memory CD8 T cells isolated from spleens and lungs of vaccinated mice. Dot plots are gated on live CD8 + cells, and numbers indicate the percentage of cells positive for both IFN and CD44.
- Memory CD8 + T-cell cytolytic activity was assessed by performing an in vivo cytotoxicity assay. Numbers reflect the percentage of antigen-specific lysis.
- C,D Quantification of relative and absolute numbers of memory CD8 ⁇ cells expressing IFN in the spleen (C) and lung (D). Absolute numbers of positive cells were determined by multiplying the relative percentage of each cell population by the total number of cells isolated from each tissue.
- E Quantification of the in vivo cytotoxicity assay presented in panel B. P.001 by one-tailed ANOVA.
- F CD127 expression on IFN + -memory CD8 T cells derived from spleens or lungs of vaccinated mice. Isotype controls are shown as filled histograms.
- G Cytokine production by memory CDS + T cells. Cells from panel F were analyzed for the ability to produce TNF and IL-2. Numbers reflect the percentage of CD8 T IFN + cells that also are positive for TNF or IL-2. In all cases, data are pooled from at least 2 independent experiments with 4 or more mice/group per experiment and plotted as means ( ⁇ SEM).
- FIGURE 3 This figure contains experiments that shoe that anti-CD40/TLR7 agonist therapeutic intervention slows the progression of metastatic melanoma.
- C57BL/6 mice were challenged with 10 5 metastatic B16.F10 melanoma cells intravenously.
- mice were vaccinated with 100 ⁇ g of the tumor-associated antigen V, 100 ⁇ g CD40 FGK45, and 100 ⁇ g S-27609 in combinations as indicated.
- mice were killed, lungs were removed, and metastatic surface tumor nodules were enumerated with the aid of a dissecting microscope.
- A Photograph of macroscopically visible tumor nodules on lungs of mice, 24 days after tumor challenge.
- FIGURE 4 This figure contains experiments relating to kinetic analysis of infiltrating lymphocytes. Shown in figure 4(A) is the experimental design and Figure 4(B) contains representative dot plots of lymphocytes isolated from metastatic target organs at day 10 or 21 after tumor challenge. Cells were isolated from tumor-bearing lungs as described in "Methods" and subjected to an in vitro restimulation with tumor peptide. Plots are gated on live, CD8 + cells. Numbers in the upper right-hand quadrant reflect the frequency of CD8 + T cells that are positive for both IFN and the activation marker CD44. Data are representative of 3 independent experiments with 4 mice per group in each experiment.
- FIGURE 5 This figure contains experiments that reveal that the hepatic toxicity associated with CD40 monotherapy is reversed with TLR7 agonism.
- C-F Histologic analysis of livers treated with PBS (C), 100 ⁇ g CD40 (D), 100 ⁇ g TLR7* (E), or 100 ⁇ g CD40 and 100 ⁇ g TLR7* (F) for 48 hours.
- FIGURE 6 This figure consisting of figure 6(A) and 6(B) contains additional experiments showing the abatement of liver toxicity by co-administration of a TLR agonist or a type 1 interferon (alpha interferon) with a anti-CD40 antibody agonist.
- hepatocellular injury was biochemically assessed by measuring serum liver enzyme activity. Specifically, mice received lOOmg anti-CD40, lOOmg S-27609 or both i.v. In some cases, mice also received graded doses of recombinant Interferon- alpha (normally, one million international units per mouse). Serum was harvested 24-72 hours later and sent to Charles River Laboratories (Worcester, MA) for liver chemistry profile analysis.
- Worcester, MA Charles River Laboratories
- the present invention provides a novel methods for alleviating or preventing toxicity, particularly liver toxicity, that is elicited by some therapies involving the administration of TNF/TNF-R agonists, e.g., liver toxicity associated with the administration of some CD40 agonists including CD40 agonistic antibodies and soluble CD40L polypeptides. It has been surprisingly discovered that such toxicity is alleviated or prevented if such therapeutic regimens further include the administration of an amount of a type 1 interferon and/or a TLR agonist sufficient to alleviate or prevent toxicity.
- the present invention reduces the adverse side effects of such therapies, as well as potentially enhancing the efficacy of such therapies as larger dosages of the TNF/TNF-R agonist, e.g., a CD40 agonist may be administered without the danger of eliciting an adverse hepatic reaction in a patient whose liver function may already be compromised because of disease.
- the subject invention in particular provides for improved (safer and more effective) methods of treating cancer, infectious diseases, autoimmune and inflammatory diseases using a TNF/TNF-R agonist in conjunction with an amount of type 1 interferon and/or TLR agonist sufficient to reduce or prevent liver toxicity that might otherwise result at the administered dosage of TNF/TNF-R agonist.
- CD40 is a reasonable target for inducing heightened CMI responses for the purposes of tumor protection, yet the data in the literature suggested that it was not applicable in a wide range of tumors.
- the inventor's laboratory has worked intensively for a number of years to try to develop a general method to enhance protective tumor immunity using an agonistic anti-CD40 antibody as a monotherapy, and failed. Any and all parameters of dose of antibody, timing, route of inoculation, tumor type, different mabs, etc were extensively tested yet these efforts proved futile, except in B lymphoma and leukemia models, as reported by Glermie.
- CD40 associated toxicity Studies in both mouse and human have shown that the administration of CD40 agonists alone induce toxicity. In intact mice, it has been shown that CD40 agonists induce liver toxicity. In immune deficient mice and non-lethally-irradiated mice, the administration of CD40 agonists induce lethality.
- this invention comprises improved (safer) therapeutic regimens involving the administration of at least one TNF/TNF-R agonist at a dosage that has been shown to elicit liver toxicity in some subjects at the requisite or desired therapeutic dosage, by the further administration of an amount of at least one type in interferon and/or at least one TLR agonist that is sufficient to reduce or eliminate potential liver toxicity elicited by the TNF/TNF-R agonist of administered as a monotherapy.
- An agonist refers to a compound that, in combination with a receptor, can produce a cellular response.
- An agonist may be a ligand that directly binds to the receptor.
- an agonist may combine with a receptor indirectly by, for example, (a) forming a complex with another molecule that directly binds to the receptor, or (b) otherwise resulting in the modification of another compound so that the other compound directly binds to the receptor.
- An agonist may be referred to as an agonist of a particular receptor or family of receptors (e.g., a TLR agonist or a TNF/R agonist).
- Antigen refers to any substance that is capable of being the target of an immune response.
- An antigen may be the target of, for example, a cell-mediated and/or humoral immune response raised by a subject organism.
- an antigen may be the target of a cellular immune response (e.g., immune cell maturation, production of cytokines, production of antibodies, etc.) when contacted with immune cells.
- a cellular immune response e.g., immune cell maturation, production of cytokines, production of antibodies, etc.
- “Co-administered” refers to two or more components of a combination administered so that the therapeutic or prophylactic effects of the combination can be greater than the therapeutic or prophylactic effects of either component administered alone. Two components may be co-administered simultaneously or sequentially.
- Simultaneously coadministered components may be provided in one or more pharmaceutical compositions.
- Sequential co-administration of two or more components includes cases in which the components are administered so that each component can be present at the treatment site at the same time.
- sequential co-administration of two components can include cases in which at least one component has been cleared from a treatment site, but at least one cellular effect of administering the component (e.g., cytokine production, activation of a certain cell population, etc.) persists at the treatment site until one or more additional components are administered to the treatment site.
- a co-administered combination can, in certain circumstances, include components that never exist in a chemical mixture with one another.
- immunostimulatory combination refers to any combination of components that can be co-administered to provide a therapeutic and/or prophylactic immunostimulatory effect.
- the components of an immunostimulatory combination can include, but are not limited to, TLR agonists, TNF/R agonists, type 1 interferons, antigens, adjuvants, and the like.
- Matture refers to any mixture, aqueous or non-aqueous solution, suspension, emulsion, gel, cream, or the like, that contains two or more components.
- the components may be, for example, two immunostimulatory components that, together, provide an immunostimulatory combination.
- the immunostimulatory components may be any combination of one or more antigens, one or more adjuvants, or both.
- a mixture may include two adjuvants so that the mixture forms an adjuvant combination.
- a mixture may include an adjuvant combination and an antigen so that the mixture forms a vaccine.
- "Synergy" and variations thereof refer to activity (e.g., immunostimulatory activity) of administering a combination of compounds that is greater than the additive activity of the compounds if administered individually.
- TLR generally refers to any Toll-like receptor of any species of organism.
- TLR agonist refers to a compound that acts as an agonist of a TLR. This includes TLRl, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLRlO, and TLRl 1 agonists or a combination thereof.
- TLR agonist compound can include the compound in any pharmaceutically acceptable form, including any isomer (e.g., diastereomer or enantiomer), salt, solvate, polymorph, and the like.
- reference to the compound can include each of the compound's enantiomers as well as racemic mixtures of the enantiomers.
- a compound may be identified as an agonist of one or more particular TLRs (e.g., a TLR7 agonist, a TLR8 agonist, or a TLR7/8 agonist).
- the TLR agonist will comprise a whole virus or microorganism which may be engineered to express a desired antigen.
- the microorganism or virus which functions as a TLR agonist may be genetically engineered to express a CD40 agonist or another TNF/TNF-R agonist, e.g., a 4-1BB agonist and/or a desired antigen thereby providing the TNF/TNF-R agonist, e.g., CD40 or 4- IBB agonist, TLR agonist and optional antigen in a single microbial or viral vehicle thereby facilitating administration to a host having a condition wherein enhanced antigen specific cellular immune response are desirably elicited.
- the TLR agonism for a particular compound may be assessed in any suitable manner.
- a compound can be identified as an agonist of a particular TLR if performing the assay with a compound results in at least a threshold increase of some biological activity mediated by the particular TLR.
- a compound may be identified as not acting as an agonist of a specified TLR if, when used to perform an assay designed to detect biological activity mediated by the specified TLR, the compound fails to elicit a threshold increase in the biological activity.
- an increase in biological activity refers to an increase in the same biological activity over that observed in an appropriate control.
- An assay may or may not be performed in conjunction with the appropriate control. With experience, one skilled in the art may develop sufficient familiarity with a particular assay (e.g., the range of values observed in an appropriate control under specific assay conditions) that performing a control may not always be necessary to determine the TLR agonism of a compound in a particular assay.
- the precise threshold increase of TLR-mediated biological activity for determining whether a particular compound is or is not an agonist of a particular TLR in a given assay may vary according to factors known in the art including but not limited to the biological activity observed as the endpoint of the assay, the method used to measure or detect the endpoint of the assay, the signal-to-noise ratio of the assay, the precision of the assay, and whether the same assay is being used to determine the agonism of a compound for multiple TLRs. Accordingly it is not practical to set forth generally the threshold increase of TLR-mediated biological activity required to identify a compound as being an agonist or a non-agonist of a particular TLR for all possible assays.
- Assays employing HEK293 cells transfected with an expressible TLR structural gene may use a threshold of, for example, at least a three-fold increase in a TLR-mediated biological activity (e.g., NF.kappa.B activation) when the compound is provided at a concentration of, for example, from about 1 .mu.M to about 10 .mu.M for identifying a compound as an agonist of the TLR transfected into the cell.
- a threshold of, for example, at least a three-fold increase in a TLR-mediated biological activity (e.g., NF.kappa.B activation) when the compound is provided at a concentration of, for example, from about 1 .mu.M to about 10 .mu.M for identifying a compound as an agonist of the TLR transfected into the cell.
- NF.kappa.B activation e.g., NF.kappa.B activation
- the TLR agonist can be a natural agonist of a TLR or a synthetic IRM compound.
- IRM compounds include compounds that possess potent immunomodulating activity including but not limited to antiviral and antitumor activity.
- Certain IRMs modulate the production and secretion of cytokines.
- certain IRM compounds induce the production and secretion of cytokines such as, e.g., Type I interferons, TNF-. alpha., IL-I, IL-6, IL-8, IL-10, IL-12, MIP-I, and/or MCP-I.
- certain IRM compounds can inhibit production and secretion of certain TH2 cytokines, such as ⁇ L-4 and IL-5. Additionally, some IRM compounds are said to suppress IL-I and TNF (U.S. Pat. No. 6,518,265).
- Certain IRMs that are useful as TLR agonists in immunostimulatory combinations of the invention are small organic molecules (e.g., molecular weight less than about 1000 Daltons, and less than about 500 Daltons in some cases), as opposed to large biological molecules such as proteins, peptides, and the like. Certain small molecule IRM compounds are disclosed in, for example, U.S. Pat. Nos.
- Additional examples of small molecule IRMs include certain purine derivatives
- IRMs include large biological molecules such as oligonucleotide sequences.
- Some IRM oligonucleotide sequences contain cytosine-guanine dinucleotides (CpG) and are described, for example, in U.S. Pat. Nos. 6,194,388; 6,207,646; 6,239,116; 6,339,068; and 6,406,705.
- CpG-containing oligonucleotides can include synthetic immunomodulatory structural motifs such as those described, for example, in U.S. Pat. Nos. 6,426,334 and 6,476,000.
- Other IRM nucleotide sequences lack CpG and are described, for example, in International Patent Publication No. WO 00/75304.
- Small molecule IRM compounds suitable for use as a TLR agonist in immuno stimulatory combinations of the invention include compounds having a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring.
- Such compounds include, for example, imidazoquinoline amines including but not limited to substituted imidazoquinoline amines such as, for example, aminoalkyl-substituted imidazoquinoline amines, amide-substituted imidazoquinoline amines, sulfonamide-substituted imidazoquinoline amines, urea-substituted imidazoquinoline amines, aryl ether-substituted imidazoquinoline amines, heterocyclic ether- substituted imidazoquinoline amines, amido ether-substituted imidazoquinoline amines, sulfonamido ether-substituted imidazoquinoline amines, urea- substituted
- the TLR agonist may be an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, or a thiazolonaphthyridine amine.
- the TLR agonist can be a sulfonamide-substituted imidazoquinoline amine.
- the TLR agonist can be a urea-substituted imidazoquinoline ether.
- the TLR agonist can be an aminoalkyl-substituted imidazoquinoline amine.
- the TLR agonist is 4-amino-. alpha., . alpha. ,2- trimethyl-lH-imidazo[4,5-c]qumolin-l-ethanol.
- the TLR agonist is N-(2- ⁇ 2-[4-amino-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethoxy- ⁇ ethyl)-N-methylmorpholine-4-carboxamide.
- the TLR agonist is l ⁇ (2 ⁇ amino-2-methylpropyl)-2-(ethoxymethyl- )-lH-imidazo[4,5-c]quinolin-4-arnine.
- the TLR agonist is N-[4-(4-amino-2-ethyl-lH-imidazo[4,5- c]quinolin-l-yl)b- utyl]methanesulfonamide.
- the TLR agonist is N-[4-(4-amino-2-propyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]me- thanesulfonamide.
- the TLR agonist may be a substituted imidazoquinoline amine, a tetrahydro imidazoquinoline amine, an imidazopyridine amine, a 1 ,2- bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, or a thiazolonaphthyridine amine.
- a substituted imidazoquinoline amine refers to an aminoalkyl- substituted imidazoquinoline amine, an amide-substituted imidazoquinoline amine, a sulfonamide-substituted imidazoquinoline amine, a urea-substituted imidazoquinoline amine, an aryl ether-substituted imidazoquinoline amine, a heterocyclic ether- substituted imidazoquinoline amine, an amido ether-substituted imidazoquinoline amine, a sulfonamido ether-substituted imidazoquinoline amine, a urea-substituted imidazoquinoline ether, or a thioether-substituted imidazoquinoline amines.
- substituted imidazoquinoline amines specifically and expressly exclude l-(2-methylpropyl)-lH-imidazo[4,5-c]qumolin-4-amin- e and 4-amino- . alpha.,. alpha. -dimethyl-2-ethoxymethyl-lH-imidazo[4,5-c]qui- nolin-1-ethanol.
- TNF-R agonist that elicits liver toxicity as a monotherapy
- dosages of a TNF-R agonist which are reported to elicit therapeutic benefits on immunity but which in clinical studies have been observed to elicit liver toxicity at least in some subjects (in the absence of co-administration of type 1 interferon and/or TLR agonist).
- TNF/R or “TNF/TNF-R” generally refers to any member of either the Tumor
- TNF Tumor Necrosis Factor
- TNFR Tumor Necrosis Factor Receptor
- the TNF Superfamily includes, for example, CD40 ligand, OX40 ligand, 4- IBB ligand, CD27, CD30 ligand (CDl 53), TNF-.alpha., TNF- .beta., RANK ligand, LT-.alpha., LT- .beta., GITR ligand, and LIGHT.
- the TNFR Superfamily includes, for example, CD40, OX40, 4-1BB, CD70 (CD27 ligand), CD30, TNFR2, RANK, LT «.beta.R, HVEM, GITR, TROY, and RELT.
- TNF/R agonist refers to a compound that acts as an agonist of a member of either the TNF Superfamily or the TNFR Superfamily.
- TNF/R agonist compound can include the compound in any pharmaceutically acceptable form, including any isomer (e.g., diastereomer or enantiomer), salt, solvate, polymorph, and the like,
- reference to the compound can include each of the compound's enantiomers as well as racemic mixtures of the enantiomers.
- a compound may be identified as an agonist of a particular member of either superfamily (e.g., a CD40 agonist).
- TNF-R Agonist or TNF/TNF-R Agonist” herein includes any suitable agonist of any member of either the TNF Superfamily or the TNF-R Superfamily that elicits toxicity, e.g.,particularlyr toxicity that is prevented or alleviated by administering such agonist in conjunction with at least one TLR agonist and/o type 1 interferon.
- a member of one Superfamily can be an agonist of a complementary member of the other Superfamily.
- CD40 ligand a member of the TNF Superfamily
- CD40 can act as an agonist of CD40 (a member of the TNFR Superfamily)
- CD40 can act as an agonist of CD40 ligand.
- suitable TNF/R agonists include, for example, CD40 ligand, OX40 ligand, 4-1BB ligand, CD27, CD30 ligand (CD153), TNF-.alpha., TNF- .beta., RANK ligand, LT-.alpha., LT- .beta., GITR ligand, LIGHT, CD40, OX40, 4-1BB, CD70 (CD27 ligand), CD30, TNFR2, RANK, LT-.beta.R, HVEM, GITR, TROY, and RELT.
- suitable TNF/R agonists include certain agonistic antibodies raised against a TNF/R (e.g., IClO and FGK4.5, each of which was raised against mouse CD40).
- TNF-R agonist monotherapy refers to a therapeutic regimen involving the administration of at least one TNF-R agonist, e.g., a CD40 agonist that does not include the concomitant administration of a TLR agonist and/or type 1 interferon. Typically such monotherapy may elicit liver toxicity in some subjects.
- Treatment site refers to the site of a particular treatment. Depending upon the particular treatment, the treatment site may be an entire organism (e.g., a systemic treatment) or any portion of an organism (e.g., a localized treatment).
- Type I interferon refers, collectively, to IFN-. alpha., IFN-. beta., IFN-omega, et al. or any mixture or combination thereof.
- type 1 interferon encompasses any type 1 interferon which elicits an enhanced CD 8+ immune response when administered proximate to or in combination with a TNF-R agonist, preferably a CD40 agonist. This includes alpha interferons, beta interferons and other types of interferons classified as type 1 interferons.
- this includes epsilon interferon, zeta interferon, and tau interferons such as tau 1 2, 3, 4, 5, 6, 7, 8, 9, and 10; Also, this includes variants thereof such as fragments, consensus interferons which mimic the structure of different type 1 interferon molecules such as alpha interferons, PEGylated versions thereof, type 1 interferons with altered glycosylation because of recombinant expression or mutagenesis, and the like. Those skilled in the art are well aware of different type 1 interferons including those that are commercially available and in use as therapeutics.
- the type 1 interferon will comprise a human type 1 interferon and most preferably a human alpha interferon.
- Vaccine refers to a pharmaceutical composition that includes an antigen.
- a vaccine may include components in addition to the antigen such as, for example, one or more adjuvants, a carrier, etc.
- the TLR agonist will comprise a whole virus or microorganism which may be engineered to express a desired antigen.
- the microorganism or virus which functions as a TLR agonist may be genetically engineered to express a CD40 agonist or 4- IBB agonist and/or a desired antigen thereby providing the CD40 or 4- IBB agonist, TLR agonist and optional antigen in a single microbial or viral vehicle thereby facilitating administration to a host having a condition wherein enhanced antigen specific cellular immune response are desirably elicited.
- the invention provides improved (safer and more efficacious) therapies including tumor and infectious disease vaccines involving the administration of a TNF-R agonist and optionally an antigen, whereby the improvement (reduced or eliminated liver toxicity) is attained by the co- administration of the TNF-R agonist with an amount of at least one TLR agonist and/or type 1 interferon sufficient to eliminate or reduce adverse toxicity that may otherwise result if the same dosage of the TNF-R agonist, e.g., a CD40 agonist is utilized as a monotherapy.
- a TNF-R agonist e.g., a CD40 agonist
- TNF-R agonist When the inventors herein state that a dosage of TNF-R agonist is toxic at a particular dosage, it is intended to mean that this dosage has been observed in clinical trials to elicit liver toxicity e.g., as manifested by an increase in some liver enzymes (transaminases) when used as a monotherapy (without TLR and/or type 1 interferon).
- liver toxicity e.g., as manifested by an increase in some liver enzymes (transaminases) when used as a monotherapy (without TLR and/or type 1 interferon).
- these therapies will include in particular conditions in which eliciting an antigen specific immune response is desirably elicited, for example a person with a chronic disease such as cancer or an infectious or allergic disorder producing said composition.
- the invention provides therapeutic compositions comprising an amount of said TNF-R agonist that has been found to elicit liver toxicity in some subjects (if used as a monotherapy), an amount of at least one type 1 interferon and/or TLR agonist sufficient to prevent or alleviate said liver toxicity, and optionally an antigen (or a nucleic acid sequence(s) that provides for the expression thereof in a suitable host, preferably human), suitable for the treatment of a disease, e.g., a diseases wherein eliciting an enhanced antigen- specific cellular immune response is therapeutically warranted.
- a disease e.g., a diseases wherein eliciting an enhanced antigen- specific cellular immune response is therapeutically warranted.
- the invention provides improved (safer and more efficacious) methods of immunotherapy comprising the administration of the subject agonist and/or cytokine combination to a host in need of such treatment in order to elicit an enhanced antigen specific cellular immune response.
- these compositions or polypeptide conjugates or nucleic acid sequences encoding these agonists and cytokine combinations will be administered to a subject with or at risk of developing a cancer, an infection, particularly a chronic infectious diseases e.g., involving a virus, bacteria or parasite; or an autoimmune, inflammatory or allergic condition.
- the invention may be used to elicit antigen specific cellular immune responses against HIV, lung cancer or melanoma.
- HIV is a well recognized example of a disease wherein protective immunity almost certainly will require the generation of potent and long-lived cellular immune responses against the virus.
- lung cancer and melanoma are both virulent cancers that result in thousands of deaths annually and for which improved and safe therapies are desired.
- this invention provides for the development of potent yet safe therapeutic therapeutics, e.g., vaccines against HIV and compositions for treating other chronic infectious diseases involving viruses, bacteria, fungi or parasites as well as proliferative diseases such as cancer, autoimmune diseases, allergic disorders, and inflammatory diseases.
- therapeutics e.g., vaccines against HIV and compositions for treating other chronic infectious diseases involving viruses, bacteria, fungi or parasites as well as proliferative diseases such as cancer, autoimmune diseases, allergic disorders, and inflammatory diseases.
- the present invention provides improved methods of therapy involving the administration of at least one TNF-R agonist, e.g., a CD40 agonist such as a CD40 agonistic antibody or a soluble CD40L polypeptide, fragment or conjugate containing, whereby the toxicity (liver toxicity) associated with such agonist if used as a monotherapy at a desired therapeutic dosage is reduced or eliminated by the further administration of a effective amount of at least one TLR agonist and/or type 1 interferon.
- a CD40 agonist such as a CD40 agonistic antibody or a soluble CD40L polypeptide, fragment or conjugate containing
- the type 1 interferon or TLR agonist eliminates or reduces liver toxicity of the TNF-R agonist.
- the TLR agonist and/or type 1 interferon and TNF/R agonist are provided (or administered, as appropriate to the form of the immuno stimulatory conjugate containing or encoding these moieties) in an amount effective to increase the immune response to a particular antigen.
- the amount of the TNF-R agonist, e.g., CD40 agonist will typically comprise a dosage that elicits toxicity (liver toxicity) in at least some subjects if administered as a monotherapy.
- the amount of the TLR agonist and/or type 1 interferon will be an amount sufficient to prevent or alleviate said toxicity and will be administered before, during or after TNF-R agonist administration.
- the TLR agonist can be administered in an amount from about 100 ng/kg to about 100 mg/kg. In many embodiments, the TLR agonist is administered in an amount from about 10 .mu.g/kg to about 10 mg/kg. In some embodiments, the TLR agonist is administered in an amount from about 1 mg/kg to about 5 mg/kg.
- the particular amount of TLR agonist that constitutes an amount effective to increase the immune response to a particular antigen depends to some extent upon certain factors including but not limited to the particular TLR agonist being administered; the particular antigen being administered and the amount thereof; the particular TNF/R agonist being administered and the amount thereof; the state of the immune system (e.g., suppressed, compromised, stimulated); the method and order of administration of the TLR agonist, the TNF/R agonist, and the antigen; the species to which the formulation is being administered; and the desired therapeutic result. Accordingly it is not practical to set forth generally the amount that constitutes an effective amount of the TLR agonist. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
- the amount of the type 1 interferon will be one sufficient to prevent or alleviate the toxicity of the TNF-R agonist if administered as a monotherapy.
- the toxicity of e.g., CD40 agonists can be alleviated if the CD40 agonist is administered in conjunction with a type 1 interferon or a TLR agonist.
- the invention provides for more effective CD40 agonist therapies as the CD40 agonist can be administered at higher dosages than heretofore described.
- the MTD (maximum tolerated dosage) of CD40L polypeptide if co-administered with a type 1 interferon or a TLR agonist may exceed 0.1 mg/kg/day by at least 1.5 fold, more preferably by at least 2-5 fold, or even 10-fold or more thereby permitting the CD40L polypeptide to be administered at MTD amounts ranging from at least about 0.15 mg/kg/day to 1.0 mg/kg/day or higher.
- This will result in more effective CD40L therapies such as in the treatment of CD40 associated malignancies and other treatments disclosed herein.
- the present invention will reduce toxicity of CD40 agonist antibody therapies and facilitate the administration of CD40 agonist antibody dosages higher than heretofore suggested.
- the MTD for an agonistic CD40L antibody reported by Vonderheide et al., J Clin. Immunol. 25(7):876-883 (2007) was 0.3 mg/kg and that dosages in excess resulted in transient liver toxicity, venous thromboembolism, grade 3 headaches and cytokine release and associated toxicity and adverse side effects such a fever and chills.
- Co-administration of the CD40 agonist antibody in association with type 1 interferon or a TLR agonist potentially allows for the MTD antibody amount to be substantially increased, e.g. by 1.5-15 or even 5-10 fold without adverse effects.
- the MTD amount for the CD40 agonistic antibody may be increased to about 0.45 mg/kg to about 3.0 mg/kg or even higher.
- the invention includes the co- administration of a CD40 agonist with an amount of type 1 interferon or TLR agonist sufficient to reduce toxic effects such as liver toxicity that would otherwise potentially result at the particular CD40 agonist dosage amount.
- the amount may vary from about
- the amount of the agonistic antibody or CD40L polypeptide may vary from about
- 0.00001 grams to about 5 grams more typically from about 0.001 grams to about 1 gram.
- a preferred MTD will exceed 0.3 mg/kg and may range from about 0.45 mg/kg to about 3 mg/kg.
- the therapeutic method involves the administration of an antigen this may be administered at amounts ranging from about 0.0001 grams to about 50 grams, more typically from about 0.1 grams to about 10 grams.
- these moieties may be administered in the same or different formulations. If administered separately the moieties may be administered in any order, typically within several hours of each other, more typically substantially proximate in time.
- the TNF/R agonist e.g. a CD40 agonist may be administered in an amount from about 100 ng/kg to about 100 mg/kg. In certain embodiments, the TNF/R agonist is administered in an amount from about 10 .mu.g/kg to about 10 mg/kg. In some embodiments, the TNF/R agonist is administered in an amount from about 1 mg/kg to about 5 mg/kg.
- the particular amount of TNF/R agonist that constitutes an amount effective to increase the immune response to a particular antigen depends to some extent upon certain factors including but not limited to the particular TNF/R agonist being administered; the particular TLR agonist being administered and the amount thereof; the particular antigen being administered and the amount thereof; the state of the immune system; the method and order of administration of the TLR agonist, the TNF/R agonist, and the antigen; the species to which the formulation is being administered; and the desired therapeutic result. Accordingly it is not practical to set forth generally the amount that constitutes an effective amount of the TNF/R agonist. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
- the imrnunostimulatory combination may further include an antigen.
- the antigen may be administered in an amount that, in combination with the other components of the combination, is effective to generate an immune response against the antigen.
- the antigen can be administered in an amount from about 100 ng/kg to about 100 mg/kg.
- the antigen may be administered in an amount from about 10 .mu.g/kg to about 10 mg/kg.
- the antigen may be administered in an amount from about 1 mg/kg to about 5 mg/kg.
- the particular amount of antigen that constitutes an amount effective to generate an immune response depends to some extent upon certain factors such as, for example, the particular antigen being administered; the particular TLR agonist being administered and the amount thereof; the particular TNF/R agonist being administered and the amount thereof; the state of the immune system; the method and order of administration of the TLR agonist, the TNF/R agonist, and the antigen; the species to which the formulation is being administered; and the desired therapeutic result. Accordingly, it is not practical to set forth generally the amount that constitutes an effective amount of the antigen. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
- the antigen may be administered simultaneously or sequentially with any component of the immunostimulatory combination.
- the antigen may be administered alone or in a mixture with one or more adjuvants (including, e.g., a TLR agonist, a type 1 interferon and/or TNF/R agonist).
- an antigen may be administered simultaneously (e.g., in a mixture) with respect to one adjuvant, but sequentially with respect to one or more additional adjuvants.
- Sequential co- administration of an antigen and other components of an immunostimulatory combination can include cases in which the antigen and at least one other component of the immunostimulatory combination are administered so that each is present at the treatment site at the same time, even though the antigen and the other component are not administered simultaneously.
- Sequential co-administration of the antigen and the other components of the immunostimulatory combination also can include cases in which the antigen or at least one of the other components of the immunostimulatory combination is cleared from a treatment site, but at least one cellular effect of the cleared antigen or other component (e.g., cytokine production, activation of a certain cell population, etc.) persists at the treatment site at least until one or more additional components of the combination are administered to the treatment site.
- an immunostimulatory combination of the invention can, in certain circumstances, include one or more components that never exist in a mixture with another component of the combination.
- the antigen can be any material capable of raising a THl immune response, which may include one or more of, for example, a CD8+ T cell response, an NK T cell response, a .gamma./.delta. T cell response, or a THl antibody response.
- Suitable antigens include but are not limited to peptides; polypeptides; lipids; glycoHpids; polysaccharides; carbohydrates; polynucleotides; prions; live or inactivated bacteria, viruses or fungi; and bacterial, viral, fungal, protozoal, tumor-derived, or organism-derived antigens, toxins or toxoids.
- certain currently experimental antigens especially materials such as recombinant proteins, glycoproteins, and peptides that do not raise a strong immune response, can be used in connection with adjuvant combinations of the invention.
- Exemplary experimental subunit antigens include those related to viral disease such as adenovirus, AIDS, chicken pox, cytomegalovirus, dengue, feline leukemia, fowl plague, hepatitis A, hepatitis B, HSV-I, HSV-2, hog cholera, influenza A, influenza B, Japanese encephalitis, measles, parainfluenza, rabies, respiratory syncytial virus, rotavirus, wart, and yellow fever.
- the antigen may be a cancer antigen or a tumor antigen.
- cancer antigen and tumor antigen are used interchangeably and refer to an antigen that is differentially expressed by cancer cells. Therefore, cancer antigens can be exploited to differentially target an immune response against cancer cells. Cancer antigens may thus potentially stimulate tumor-specific immune responses. Certain cancer antigens are encoded, though not necessarily expressed, by normal cells. Some of these antigens may be characterized as normally silent (i.e., not expressed) in normal cells, those that are expressed only at certain stages of differentiation, and those that are temporally expressed (e.g., embryonic and fetal antigens).
- cancer antigens can be encoded by mutant cellular genes such as, for example, oncogenes (e.g., activated ras oncogene), suppressor genes (e.g., mutant p53), or fusion proteins resulting from internal deletions or chromosomal translocations. Still other cancer antigens can be encoded by viral genes such as those carried by RNA and DNA tumor viruses.
- Cancers or tumors and specific tumor antigens associated with such tumors include acute lymphoblastic leukemia (etv6, amll, cyclophilin b), B cell lymphoma (Ig-idiotype), glioma (E-cadherin, . alpha.
- Immunostimulatory combinations of the invention that include an antigen may form a vaccine. Such vaccines can contain additional pharmaceutically acceptable ingredients, excipients, carriers, and the like well known to those skilled in the art.
- Immunostiraulatory combinations of the invention can be administered to animals, e.g., mammals (human and non-human), fowl, and the like according to conventional methods well known to those skilled in the art (e.g., orally, subcutaneous Iy, nasally, topically).
- the invention also provides therapeutic and/or prophylactic methods that include administering an immuno stimulatory combination of the invention to a subject.
- components of the immunostimulatory combination may be administered simultaneously with the antigen (together in admixture or separately, e.g., orally or by separate injection) or subsequent to administering one or more other components of the immunostimulatory combination.
- a TLR agonist or a type 1 interferon and a TNF/R agonist may be administered simultaneously with one another or sequentially with respect to each other.
- an antigen when present as a component of the immunostimulatory combination, it may be administered simultaneously with, or sequentially with respect to, any other component of the combination.
- Components of the immunostimulatory combination can be administered simultaneously or sequentially in any order.
- the components When the components are administered simultaneously, they can be administered in a single formulation or in distinct formulations. When administered as distinct formulations, whether simultaneously or sequentially, the components may be administered at a single site or at separate sites. Also, when administered as distinct formulations, each formulation may be administered using a different route. Suitable routes of administration include but are not limited to transdermal or transmucosal absorption, injection (e.g., subcutaneous, intraperitoneal, intramuscular, intravenous, etc.), ingestion, inhalation, and the like.
- the time between administration of the components can be determined, at least in part, by certain factors such as, for example, the length of time a particular component persists, either systemically or at the administration site; or the length of time that the cellular effects of the component persist, either systemically or at the administration site, even after the component has been cleared.
- Certain small molecule IRM compounds can induce biosynthesis of antiviral cytokines. Therefore, for certain embodiments that include a live viral antigen and a small molecule IRM compound as the TLR agonist component of the immunostimulatory combination, it may be desirable to administer the antigen prior to administering the IRM compound so that the viral infection can be established.
- methods of the invention can include administering a vaccine including an immunostimulatory combination of the invention to induce a THl immune response in a subject.
- an immunostimulatory combination that includes a TLR agonist e.g., a small molecule IRM
- a TNF/R agonist can provide an even greater immune response than either an antigen alone, an antigen combined with a TLR agonist, or an antigen combined with a TNF/R agonist.
- an immunostimulatory combination that includes a TLR agonist and a TNF/R agonist can synergistically increase an immune response compared to either a TLR agonist or TNF/R agonist.
- Methods of the invention also include inducing an immune response from cells of the immune system regardless of whether the cells are in vivo or ex vivo.
- an immunostimulatory combination of the invention may be useful as a component of a therapeutic vaccine, a component of a prophylactic vaccine, or as an immunostimulatory factor used in ex vivo cell culture.
- the immune cells activated ex vivo may be reintroduced into a patient.
- factors secreted by the activated immune cells in the cell culture e.g., antibodies, cytokines, co-stimulatory factors, and the like
- Methods of the invention also include activating naive CD8+ T cells in an antigen-specific manner in vivo.
- the population of activated antigen- specific CD8+ T cells produced in response to co-administration of an antigen and an immunostimulatory combination- -whether or not the antigen is explicitly a component of the immunostimulatory combination- may be divided into two functionally distinct sub-populations.
- One population of antigen- specific CD8+ T cells includes effector T cells,— CD8 + T cells actively engaged in providing a cell-mediated immune response.
- a second population of antigen-specific CD8+ T cells includes memory T cells, CD8+ T cells that are not themselves involved in providing an immune response, but can be readily induced to become antigen-specific effector cells upon a later contact with the same antigen.
- Activation of CD8+ T cells according to the following method may induce expansion of antigen-specific CD8+ effector T cells, generate antigen-specific CD8+ memory T cells, or both.
- An immunostimulatory combination that includes an antigen may be administered to a subject. After sufficient incubation in the subject, CD8.+ T cells will mature to antigen- specific CD8+ effector T cells in response to the immunization. A greater percentage of CD8+ effector T cells will be antigen-specific in subjects immunized with an immunostimulatory combination that includes a TLR agonist and a TNF/R agonist compared to subjects immunized with only antigen, antigen and a TNF/R agonist, or antigen and a TLR agonist. Generally, the incubation time between immunization and the generation of CD8+ effector T cells is from about 4 days to about 12 days. In certain embodiments, CD8+ effector T cells may be generated in about 5 days after immunization. In other embodiments, CD8.+ effector T cells may be generated in about 7 days after immunization.
- the antigen is a protein, it may not be necessary to administer the entire protein to the subject.
- a method that includes administering to a subject an immunostimulatory combination of the invention may be used to elicit an antigen-specific response in CD8+ cytotoxic T lymphocytes (CTLs) of the subject.
- CTLs cytotoxic T lymphocytes
- Such a response may be directed against many conditions including, for example, tumors and virus-infected cell populations.
- a vaccine of the invention may be administered prophylactically to provide a subject with a protective antigen- specific cell-mediated immunity directed against, for example, tumors and/or viral infections.
- immunostimulatory combinations of the present invention may be used to develop antigen-specific CD8.+ memory T cells in vivo.
- the antigen- specific CD8+ memory T cells may be capable of generating a secondary THl immune response upon a second exposure to the antigen.
- CD8+ effector T cells may be generated from the reactivated CD8+ memory T cells in as little as 2 hours after re-exposure to the antigen.
- the second exposure to the antigen may be by immunization (i.e., a booster immunization) or natural exposure.
- An immunostimulatory combination of the invention can be used to therapeutically treat a condition treatable by a cell-mediated immune response.
- Such a combination can contain at least a therapeutically effective amount of a TLR agonist and a therapeutically effective amount of a TNF/R agonist.
- a therapeutic combination can further include a therapeutically effective amount of an antigen.
- a therapeutic combination can be provided in further combination with one or more pharmaceutically acceptable carriers. Because the TLR agonist and/or type 1 interferon, TNF/R agonist, and antigen (if present in the combination) may be co-administered sequentially, at different sites, and/or by different routes, a therapeutic combination may be provided in two or more formulations.
- each formulation can include a carrier similar or different than the carrier or carriers included in the remaining formulations.
- the TLR agonist, and/or type 1 interferon TNF/R agonist, and antigen may be provided in a single formulation, which can include a single carrier or a combination of carriers.
- Each component or mixture of components may be administered in any suitable conventional dosage form such as, for example, tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like,
- Therapeutic immuno stimulatory combinations can be administered as the single therapeutic agent in the treatment regimen.
- a therapeutic immunostimulatory combination of the invention may be administered in combination with another therapeutic combination of the invention, with one or more pharmaceutical compositions, or with other active agents such as antivirals, antibiotics, additional IRM compounds, etc.
- certain immunostimulatory combinations of the invention can be particularly useful for treating viral diseases and tumors.
- immunostimulatory combinations and vaccines of the invention are useful in treating conditions such as, but not limited to: [0099] (a) viral diseases such as, for example, diseases resulting from infection by an adenovirus, a herpesvirus (e.g., HSV-I, HSV-II, CMV, or VZV), a poxvirus (e.g., an orthopoxvirus such as variola or vaccinia, or molluscum contagiosum), a picomavirus (e.g., rhinovirus or enterovirus), an orthomyxovirus (e.g., influenzavirus), a paramyxovirus (e.g., parainfluenzavirus, mumps virus, measles virus, and respiratory syncytial virus (RSV)), a coronavirus (e.g., SARS), a papovavirus (e.g., papillomaviruses, such as those that cause genital warts,
- a viral diseases
- (c) other infectious diseases such chlamydia, fungal diseases including but not limited to candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, or parasitic diseases including but not limited to malaria, Pneumocystis carnii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and trypanosome infection; and
- neoplastic diseases such as, for example, intraepithelial neoplasias, cervical dysplasia, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, renal cell carcinoma, Kaposi's sarcoma, lung cancer, melanoma, renal cell carcinoma, leukemias including but not limited to myelogeous leukemia, chronic lymphocytic leukemia, multiple myeloma, non- Hodgkin's lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma, and hairy cell leukemia, and other cancers (e.g., cancers identified above); and
- TH2 -mediated, atopic, and autoimmune diseases such as atopic dermatitis or eczema, eosinophilia, asthma, allergy, allergic rhinitis, systemic lupus erythematosus, essential thrombocythaemia, multiple sclerosis, Ommen's syndrome, discoid lupus, alopecia areata, inhibition of keloid formation and other types of scarring, and enhancing would healing, including chronic wounds.
- Some embodiments of the immunostimulatory combinations of the invention also may be useful as a vaccine adjuvant for use in conjunction with any material that raises either humoral and/or cell mediated immune response, such as, for example, live viral, bacterial, or parasitic antigens; inactivated viral, tumor- derived, protozoal, organism-derived, fungal, or bacterial antigens, toxoids, toxins; self-antigens; polysaccharides; proteins; glycoproteins; peptides; cellular vaccines; DNA vaccines; recombinant proteins; glycoproteins; peptides; and the like, for use in connection with, for example, BCG, cholera, plague, typhoid, hepatitis A, hepatitis B, hepatitis C, influenza A, influenza B, parainfluenza, polio, rabies, measles, mumps, rubella, yellow fever, tetanus, diphtheria, hemophilus influenza
- Immunostimulatory combinations of the invention may also be particularly helpful in individuals having compromised immune function.
- IRM compounds may be used for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV patients.
- the invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of an immuno stimulatory combination of the invention to the animal.
- a therapeutically effective amount to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals
- a therapeutically effective amount of a combination to treat a neoplastic condition is an amount that will cause, for example, a reduction in tumor size, a reduction in the number of tumor foci, or slow the growth of a tumor, as compared to untreated animals, [00107]
- an immunostimulatory combination of the invention may be used to inhibit tumor growth in vivo.
- Subjects having tumor cells expressing a particular antigen may be immunized with a therapeutic combination that contains a TLR agonist, a TNF/R agonist, and, optionally, the antigen.
- the therapy can include an initial immunization and a second booster immunization. Tumors taken from subjects immunized with a therapeutic combination of the invention were generally smaller than the tumors harvested from either (a) non-immunized subjects, or (b) subjects immunized with only the antigen.
- Treatments according to the present invention may include one or more than one immunization.
- the treatment can include any suitable number of immunizations administered at any suitable frequency.
- the number and frequency of immunizations in a treatment regimen depend at least in part upon one or more factors including but not limited to the condition being treated and the stage thereof, the state of the subject's immune system, the particular TLR agonist or type 1 interferon being administered and the amount thereof, the particular TNF/R agonist being administered and the amount thereof, and the particular antigen being administered (if present) and the amount thereof.
- therapeutic combinations of the invention may not require an antigen component.
- an antigen component e.g., B cell lymphoma or chronic bacterial or viral infections
- effective treatment may be obtained using an immunostimulatory combination that does not include an antigen.
- Such conditions may be treatable in this way because, for example, the condition may provide a sufficient quantity or variety of condition- specific antigens to generate a cell-mediated immune response capable of treating the condition.
- the TLR agonist and/or type 1 interferon and TNF/R agonist are provided (or administered, as appropriate to the form of the immunostimulatory combination) in an amount effective to increase the immune response to a particular antigen and at a dosage wherein the TNF-R agonist may elicit liver toxicity as a monotherapy.
- the TLR agonist can be administered in an amount from about 100 ng/kg to about 100 mg/kg. In many embodiments, the TLR agonist is administered in an amount from about 10 ,mu,g/kg to about 10 mg/kg. In some embodiments, the TLR agonist is administered in an amount from about 1 mg/kg to about 5 mg/kg.
- the particular amount of TLR agonist that constitutes an amount effective to increase the immune response to a particular antigen depends to some extent upon certain factors including but not limited to the particular TLR agonist being administered; the particular antigen being administered and the amount thereof; the particular TNF/R agonist being administered and the amount thereof; the state of the immune system (e.g., suppressed, compromised, stimulated); the method and order of administration of the TLR agonist, the TNF/R agonist, and the antigen; the species to which the formulation is being administered; and the desired therapeutic result. Accordingly it is not practical to set forth generally the amount that constitutes an effective amount of the TLR agonist. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
- the TNF/R agonist may be administered in an amount from about 100 ng/kg to about 100 mg/kg. In certain embodiments, the TNF/R agonist is administered in an amount from about 10 .mu.g/kg to about 10 mg/kg. In some embodiments, the TNF/R agonist is administered in an amount from about 1 mg/kg to about 5 mg/kg.
- the particular amount of TNF/R agonist that constitutes an amount effective to increase the immune response to a particular antigen depends to some extent upon certain factors including but not limited to the particular TNF/R agonist being administered; the particular TLR agonist being administered and the amount thereof; the particular antigen being administered and the amount thereof; the state of the immune system; the method and order of administration of the TLR agonist, the TNF/R agonist, and the antigen; the species to which the formulation is being administered; and the desired therapeutic result. Accordingly it is not practical to set forth generally the amount that constitutes an effective amount of the TNF/R agonist. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
- the immuno stimulatory combination may further include an antigen.
- the antigen may be administered in an amount that, in combination with the other components of the combination, is effective to generate an immune response against the antigen.
- the antigen can be administered in an amount from about 100 ng/kg to about 100 mg/kg.
- the antigen may be administered in an amount from about 10 .mu.g/kg to about 10 mg/kg.
- the antigen may be administered in an amount from about 1 mg/kg to about 5 mg/kg.
- the particular amount of antigen that constitutes an amount effective to generate an immune response depends to some extent upon certain factors such as, for example, the particular antigen being administered; the particular TLR agonist being administered and the amount thereof; the particular TNF/R agonist being administered and the amount thereof; the state of the immune system; the method and order of administration of the TLR agonist, the TNF/R agonist, and the antigen; the species to which the formulation is being administered; and the desired therapeutic result. Accordingly, it is not practical to set forth generally the amount that constitutes an effective amount of the antigen. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
- the antigen may be administered simultaneously or sequentially with any component of the immuno stimulatory combination.
- the antigen may be administered alone or in a mixture with one or more adjuvants (including, e.g., a TLR agonist and/or type 1 interferon, a TNF/R agonist, or a combination thereof).
- an antigen may be administered simultaneously (e.g., in a mixture) with respect to one adjuvant, but sequentially with respect to one or more additional adjuvants.
- Sequential co-administration of an antigen and other components of an immunostimulatory combination can include cases in which the antigen and at least one other component of the immunostimulatory combination are administered so that each is present at the treatment site at the same time, even though the antigen and the other component are not administered simultaneously.
- Sequential co-administration of the antigen and the other components of the immunostimulatory combination also can include cases in which the antigen or at least one of the other components of the immunostimulatory combination is cleared from a treatment site, but at least one cellular effect of the cleared antigen or other component (e.g., cytokine production, activation of a certain cell population, etc.) persists at the treatment site at least until one or more additional components of the combination are administered to the treatment site.
- an immunostimulatory combination of the invention can, in certain circumstances, include one or more components that never exist in a mixture with another component of the combination.
- the invention also provides therapeutic and/or prophylactic methods that include administering an immunostimulatory combination of the invention to a subject.
- the methods and compositions can be used to treat an individual at risk of having an infection or has an infection by including an antigen from the infectious agent.
- An infection refers to a disease or condition attributable to the presence in the host of a foreign organism or an agent which reproduce within the host.
- a subject at risk of having an infection is a subject that is predisposed to develop an infection.
- Such an individual can include for example a subject with a known or suspected exposure to an infectious organism or agent.
- a subject at risk of having an infection can also include a subject with a condition associated with impaired ability to mount an immune response to an infectious agent or organism, for example a subject with a congenital or acquired immunodeficiency, a subject undergoing radiation or chemotherapy, a subject with a burn injury, a subject with a traumatic injury, a subject undergoing surgery, or other invasive medical or dental procedure, or similarly immunocompromised individual.
- Infections which may be treated or prevented with the vaccine compositions of this invention include bacterial, viral, fungal, and parasitic.
- infection also include are rickettsiae, mycoplasms, and agents causing scrapie, bovine spongiform encephalopathy (BSE), and prion diseases (for example kuru and Creutzfeldt-Jacob disease).
- BSE bovine spongiform encephalopathy
- prion diseases for example kuru and Creutzfeldt-Jacob disease.
- An infection may be acute, subacute, chronic or latent and it may be localized or systemic.
- the infection can be predominantly intracellular or extracellular during at least one phase of the infectious organism's agent's life cycle in the host.
- Bacteria infections against which the subject vaccines and methods may be used include both Gram negative and Gram positive bacteria.
- Gram positive bacteria include but are not limited to Pasteurella species, Staphylococci species, and Streptococci species.
- Gram negative bacteria include but are not limited to Escherichia coli, Pseudomonas species, and Salmonella species,.
- infectious bacteria include but are not limited to Heliobacter pyioris, Borrelia burgdorferi, Legionella pneumophilia, Mycobacteria spp. (for example M. tuberculosis, M. avium, M. intracellilare, M. kansaii, M.
- Retroviridae for example human deficiency viruses, such as HIV-I (also referred to as HTLV- III), HIV-II, LAC or IDLV-III/LAV or HIV-III and other isolates such as HIV-LP, Picornaviridae (for example poliovirus, hepatitis A, enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses), Calciviridae (for example strains that cause gastroenteritis), Togaviridae (for example equine encephalitis viruses, rubella viruses), Flaviviridae (for example dengue viruses, encephalitis viruses, yellow fever viruses) Coronaviridae (for example coronaviruses), Rhabdoviridae (for example vesicular stomata viruses, rabies viruses), Filoviridae(for example Ebola viruses) Paramyxoviridae (for example parainfluenza viruses, mumps viruses, measles virus, respiratory
- fungi examples include Aspergillus spp., Coccidoides immitis, Cryptococcus neoformans, Candida albicans and other Candida spp., Blastomyces dermatidis, Histoplasma capsulatum, Chlamydia trachomatis, Nocardia spp., and Pneumocytis carinii.
- Parasites include but are not limited to blood-borne and/or tissue parasites such as
- this invention further embraces the use of the subject therapeutic regimens and compositions in treating proliferative diseases such as cancers.
- Cancer is a condition of uncontrolled growth of cells which interferes with the normal functioning of bodily organs and systems.
- a subject that has a cancer is a subject having objectively measurable cancer cells present in the subjects' body.
- a subject at risk of developing cancer is a subject predisposed to develop a cancer, for example based on family history, genetic predisposition, subject exposed to radiation or other cancer-causing agent. Cancers which migrate from their original location and seed vital organs can eventually lead to the death of the subject through the functional deterioration of the affected organ.
- Hematopoietic cancers such as leukemia, are able to out-compete the normal hematopoietic compartments in a subject thereby leading to hematopoietic failure (in the form of anemia, thrombocytopenia and neutropenia), ultimately causing death.
- a metastasis is a region of cancer cells, distinct from the primary tumor location, resulting from the dissemination of cancer cells from the primary tumor to other parts of the body.
- the subject may be monitored for the presence of metastases. Metastases are often detected through the sole or combined use of magnetic resonance imaging (MRI), computed tomography (CT), scans, blood and platelet counts, liver function studies, chest -X-rays and bone scans in addition to the monitoring of specific symptoms.
- MRI magnetic resonance imaging
- CT computed tomography
- the adjuvant combinations and compositions containing according to the invention can be used to treat a variety of cancers or subjects at risk of developing cancer, by the inclusion of a tumor-associated-antigen (TAA) 5 or DNA encoding.
- TAA tumor-associated-antigen
- This is an antigen expressed in a tumor cell.
- cancers include breast, prostate, colon, blood cancers such as leukemia, chronic lymphocytic leukemia, and the like.
- the vaccination methods of the invention can be used to stimulate an immune response to treat a tumor by inhibiting or slowing the growth of the tumor or decreasing the size of the tumor.
- a tumor associated antigen can also be an antigen expressed predominantly by tumor cells but not exclusively.
- Additional cancers include but are not limited to basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and central nervous system (CNS) cancer, cervical cancer, choriocarcinoma, colorectal cancers, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, intraepithelial neoplasm, kidney cancer, larynx cancer, liver cancer, lung cancer (small cell, large cell), lymphoma including Hodgkin's lymphoma and non-Hodgkin's lymphoma; melanoma; neuroblastoma; oral cavity cancer(for example lip, tongue, mouth and pharynx);ovarian cancer; pancreatic cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of
- the adjuvant combinations and compositions containing according to the invention can also be used to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, type 1 diabetes, psoriasis or other autoimmune disorders.
- Other autoimmune disease which potentially may be treated with the vaccines and immune adjuvants of the invention include Crohn's disease and other inflammatory bowel diseases such as ulcerative colitis, systemic lupus eythematosus (SLE), autoimmune encephalomyelitis, myasthenia gravis (MG), Hashimoto's thyroiditis, Goodpasture's syndrome, pemphigus, Graves disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polypyositis, pernicious anemia, idiopathic Addison's disease, autoimmune associated infertility, glomerulonephritis )for example crescentic
- the adjuvant combinations and compositions containing according to the invention can also be used to treat asthma and allergic and inflammatory diseases.
- Asthma is a disorder of the respiratory system characterized by inflammation and narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently although not exclusively associated with atopic or allergic symptoms. Allergy is acquired hypersensitivity to a substance (allergen). Allergic conditions include eczema, allergic rhinitis, or coryza, hay fever, bronchial asthma, urticaria, and food allergies and other atopic conditions.
- An allergen is a substance that can induce an allergic or asthmatic response in a susceptible subject. There are numerous allergens including pollens, insect venoms, animal dander, dust, fungal spores, and drugs.
- Examples of natural and plant allergens include proteins specific to the following genera: Canine, Dermatophagoides, Felis, Ambrosia, Lotium, Cryptomeria, Alternaria, Alder, Alinus, Betula, Quercus, Olea, Artemisia, Plantago, Parietaria, Blatella, Apis, Cupressus, Juniperus, Thuya, Chamaecyparis, Periplanet, Agopyron, Secale, Triticum, Dactylis, Festuca, Poa, Avena, Holcus, Anthoxanthum, Arrhenatherum, Agrostis, Phleum, Phalaris, Paspalum, Sorghum, and Bromis.
- the adjuvant combinations and compositions containing according to the invention can be combined with other therapies for treating the specific condition, e.g., infectious disease, cancer or autoimmune condition.
- the inventive methods may be combined with chemotherapy or radiotherapy.
- moieties include relatively small molecules that do not interfere with the function of the adjuvant combination.
- the tags may be removable by cleavage. Examples of such tags include poly-histidine tags, hemagglutinin tags, maltase binding protein, lectins, glutathione-S transferase, avidin and the like.
- the subject adjuvant combinations can be administered with a physiologically acceptable carrier such as physiological saline.
- the composition may also include another carrier or excipient such as buffers, such as citrate, phosphate, acetate, and bicarbonate, amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins such as serum albumin, ethylenediamine tetraacetic acid, sodium chloride or other salts, liposomes, marmitol, sorbitol, glycerol and the like.
- the adjuvants of the invention can be formulated in various ways, according to the corresponding route of administration.
- liquid formulations can be made for ingestion or injection, gels or procedures can be made for ingestion, inhalation, or topical application.
- Methods for making such formulations are well known and can be found in for example, "Remington's Pharmaceutical Sciences,” 18 th Ed., Mack Publishing Company, Easton Pa.
- the invention also embraces DNA based vaccines. These DNAs which may encode a desired antigen and/or CD40 adjuvant may be administered as naked DNAs, or may be comprised in an expression vector such as a recombinant virus that functions as the TLR agonist. Furthermore, the subject nucleic acid sequences may be introduced into a cell of a graft prior to transplantation of the graft. This DNA preferably will be humanized to facilitate expression in a human subject.
- the subject adjuvant combinations may further include a "marker” or "reporter”.
- marker or reporter molecules examples include beta lactamase, chloramphenicol acetyltransferase, adenosine deaminase, aminoglycoside phosphotransferase, dihydro folate reductase, hygromycin B-phosphotransferase, thymidine kinase, lacZ, and xanthine guanine phosphoribosyltransferase et al.
- the subject adjuvants may be expressed by a cell comprising a vector or vectors capable of directing the expression of an antigen or TNF-R agonist and/or type 1 interferon or
- TLR agonist for example a cell transduced with the vector.
- a baculovirus vector can be used.
- Other vectors which may be used include T7 based vectors for use in bacteria, yeast expression vectors, mammalian expression vectors, viral expression vectors, and the like.
- Viral vectors include retroviral, adenoviral, adeno-associated vectors, herpes virus, simian virus 40, and bovine papilloma virus vectors.
- bacterial and yeast expression vectors may be utilized.
- the cells can be administered either by an implantation procedure or with a catheter-mediated injection procedure through the blood vessel wall.
- the cells may be administered by release into the vasculature, from which the cells subsequently are distributed by the blood stream and/or migrate into the surrounding tissue.
- CD40 agonists as the TNF-R agonist, such agonist will preferably comprise an agonistic anti-CD40 antibody or fragment thereof that specifically binds CD40, preferably murine or human CD40, or a CD40L protein, derivative, multimer such as a trimeric CD40L or 4- IBB ligand conjugate .
- antibody is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as antigen binding fragments thereof. This includes Fab, F(ab')2, Fd and Fv fragments.
- IM7 CD127 (A7R34), CD122 (5H4), IL-2 (JES6-5H4), IFN (XMG1.2), FoxP3 (FJK-16s),
- Granzyme B (16G6), and the isotype control rat IgG2a were purchased from eBioscience (San).
- Anti-CD107a (1D4B) was purchased from
- CD40 (FGK45) was purchased from BioExpress (Lebanon, NH). Endotoxin content was less than 1 EU/mg as assessed by a quantitative chromogenic limulus amebocyte lysate kit (QCL 1000; Cambrex,East Rutherford, NJ).
- the TLR7 agonist S-27609 was a gift from 3M Pharmaceuticals (St Paul, MN) and has been previously described.
- - Anti-CD4 (GKl.5), anti-CD8 (2.43), and anti-NKl .l (PKl 36) were produced by hybridomas, and bioreactor supematants were purified using Standard methodologies.
- H2K b -restricted class I peptides Ova( 2 57 -2 64 ) (SIINFEKL) and TRP2 (I 80 -i 88 ⁇ (SVYDFFVWL) and the modified TRP2 epitope V (SIYDFFVWL) were purchased from Pepceuticals (Nottingham, United Kingdom) and were more than 90% pure. Peptides were dissolved at 5 mg/niL in DMSO and subsequently diluted in phosphate-buffered saline (PBS) for immunization.
- PBS phosphate-buffered saline
- mice were injected with 10 5 B16.F10 melanoma tumor cells intravenously to establish lung metastases.
- naive or tumor-bearing mice were intravenously vaccinated with 100 ⁇ g V peptide, 100 ⁇ g anti-CD40, and 100 ⁇ g of the TLR7 agonist S-27609 in various combinations as indicated.
- Lungs were harvested approximately 20 days later, and metastases were enumerated with the aid of a dissection microscope. Alternatively, mice were monitored for survival over the next 90 days.
- lymphocyte subsets were accomplished by intraperitoneal administration of 250 ⁇ g anti-CD4 (GKl .5), anti-CD8 (2.43), and anti-NKl . l (PK136).
- Antibodies were delivered 4 days before the start of experimentation and weekly thereafter.
- naive syngeneic splenocytes were differentially labeled with either 0.5 ⁇ M or 5 ⁇ M carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) for 10 minutes at 37°C, washed, and then pulsed for 1 hour with 20 ⁇ g/mL irrelevant Ova(257-264) (SIINFEKL) or antigen-specific TRP2 ( iso-i 88 ) peptide, respectively.
- CFSE carboxyfluorescein succinimidyl ester
- IINFEKL irrelevant Ova(257-264)
- IINFEKL antigen-specific TRP2
- mice were killed and splenocytes were analyzed by flow cytometry.
- % specific lysis (1 - [ratio of CFSE 10 ZCFSE 111 in naive mice ⁇ ratio of CFSE l0 /CFSE hi in immunized mice]
- Hepatocellular injury was biochemically assessed by measuring serum liver enzyme activity. Specifically, mice received 100 ⁇ g anti-CD40, 100 ⁇ g S-27609, or both intravenously or PBS as a control. Serum was harvested 24 to 72 hours later and levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined by standard clinical assays at the National Jewish Medical Center Core Lab (Denver, CO). For histologic analysis, livers from mice treated as above were fixed in buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) prior to being coded and scored on a 0 to 4 scale in a blinded fashion.
- H&E hematoxylin and eosin
- liver 0 indicates normal liver, no lesions or hepatocellular damage noted; 1, rare portal and parenchymal infiltrates but no necrosis; 2, moderate parenchymal or portal infiltrates but no necrosis; 3, frequent and/or large portal or parenchymal infiltrates with occasional isolated islands of coagulative necrosis; and 4, extensive areas of inflammation with bridging coagulative necrosis.
- H&E images were acquired via an Olympus BX41 microscope (Center Valley, PA) using a 20x/0.05 non-oil objective and 1Ox ocular attached to an Olympus DPI 1 digital camera and were edited with XnVi ew for Windows, version 1.82.2 (Reims, France).
- CD40 V plus agonistic CD40 antibody
- TLR7* TLR7 agonist
- CD40 increased the relative number of CD8 + T cells in the peripheral blood of immunized mice, regardless of the addition of antigen, TLR7 agonist, or both (P.001 for V/CD40, V/CD40/TLR7*, and CD40/TLR7* compared with V alone). While CD40 increased polyclonal CD8 + responses, it failed to generate a substantial population of TRP2-specific CD8 + T cells ( Figure 1 A,C).
- CD40/TLR7* vaccination elicits potent CD8 + T-cell memory
- mice vaccinated with this regimen efficiently lysed peptide-pulsed targets when subjected to an in vivo cytotoxicity assay ( Figure 2B,E; P.OO1, compared with either V or V/CD40).
- mice were immunized with 100 ⁇ g each of V peptide, CD40, and S-27609 in combinations as indicated. Memory CD8 4" functionality was assessed 65 days later.
- A Representative dot plots of IFN secretion by memory CD8 + T cells isolated from spleens and lungs of vaccinated mice. Dot plots are gated on live CD8 + cells, and numbers indicate the percentage of cells positive for both IFN and CD44.
- C,D Quantification of relative and absolute numbers of memory CDS + cells expressing IFN in the spleen (C) and lung (D). Absolute numbers of positive cells were determined by multiplying the relative percentage of each cell population by the total number of cells isolated from each tissue.
- E Quantification of the in vivo cytotoxicity assay presented in panel B. P.001 by one-tailed ANOVA.
- F CDl 27 expression on IFN + -memory CD8 + T cells derived from spleens or lungs of vaccinated mice. Isotype controls are shown as filled histograms.
- G Cytokine production by memory CD8 + T cells. Cells from panel F were analyzed for the ability to produce TNF and IL-2. Numbers reflect the percentage of CD8 + IFN + cells that also are positive for TNF or IL-2. In all cases, data are pooled from at least 2 independent experiments with 4 or more mice/group per experiment and plotted as means ( ⁇ SEM).
- mice were intravenously inoculated with 10 5 metastatic Bl 6.F 10 melanoma cells and treatment was initiated 4 days later. Twenty- four days after vaccination, mice were killed and surface lung metastases were enumerated. Treatment with tumor antigen or tumor antigen plus a TLR7 agonist was ineffective in controlling tumor progression (Figure 3A 5 B)- Immunization with tumor antigen plus CD40 reduced the number of tumor nodules (P.001 vs V alone).
- mice were challenged with 10 5 metastatic B16.F10 melanoma cells intravenously. Four days later, mice were vaccinated with 100 ⁇ g of the tumor- associated antigen V, 100 ⁇ g CD40 FGK45, and 100 ⁇ g S-27609 in combinations as indicated. After 24 days, mice were killed, lungs were removed, and metastatic surface tumor nodules were enumerated with the aid of a dissecting microscope.
- A Photograph of macroscopically visible tumor nodules on lungs of mice, 24 days after tumor challenge. Numbers below the lungs reflect the mean survival time and long-term survival rate of mice monitored for therapeutic efficacy. Data are pooled from 3 to 4 independent experiments with greater than 8 mice per group in each experiment.
- FIG. 4 Shown in figure 4(A) is the experimental design, and Figure 4(B) contains representative dot plots of lymphocytes isolated from metastatic target organs at day 10 or 21 after tumor challenge.
- Cells were isolated from tumor-bearing lungs as described in "Methods" and subjected to an in vitro restimulation with tumor peptide. Plots are gated on live, CD8 + cells. Numbers in the upper right-hand quadrant reflect the frequency of CDS + T cells that are positive for both IFN and the activation marker CD44. Data are representative of 3 independent experiments with 4 mice per group in each experiment.
- C,D Quantification of lung infiltrates at either 10 (C) or 21 (D) days after tumor challenge.
- Vaccine efficacy must overcome the effect of regulatory T cells, and the ratio of
- CD8 + /FoxP3 + cells has been used to assess priming strength.
- CD40-induced hepatocellular injury is reduced by coadministration of TLR7 agonist
- mice received 100 mg anti-CD40, 100 mg S-27609 or both FV. In some cases mice also received graded doses of recombinant interferon alpha (normally, one million international units per mouse). Serum was harvested 24-72 hours later and sent to Charles River Laboratories
- Alum is salts of aluminum hydroxide and phosphate and primarly elicits humoral-mediated immune responses. This adjuvant was first employed in 1926 and was effectively grandfathered in when the FDA first assumed new drug approval authority in 1938. Alum is the only FDA approved adjuvant, and is a component of a number of our commonly used vaccines, like tentanus toxoid.
- Non-cytokme There are many other adjuvants (non-cytokme) that have been employed in cancer clinical trials like Bacille Calmette-Guerin (BCG), keyhole limpet hemocyanin (KLH), incomplete Freund's adjuvant (IFA), all which have poorly understood mechanisms of action and modest adjuvant activities. Not until 1999, when the first studies elucidating the receptors for immune adjuvants (Toll-like receptors) emerged on the horizon, did a molecular understanding of how these "non-specific" activators of the immune system trigger innate immunity.
- BCG Bacille Calmette-Guerin
- KLH keyhole limpet hemocyanin
- IFA incomplete Freund's adjuvant
- TLRs are type 1 membrane proteins that are expressed on hematopoietic and non-hematopoietic cells. Currently, there are 1 1 members in the TLR family. These receptors are characterized by their capacity to recognize pathogen- associated molecular patterns (PAMP) expressed by pathogenic organisms. Typical PAMPS include LPS, DNA (CpG), lipoproteins, ssRNA, and glycolipids, as detailed in the Table I below. Whether there are true endogenous Hgands for TLRs is still controversial, although it has been reported that TLR2 and TLR4 are able to recognize several self-proteins including members of heat shock protein family hsp ⁇ O and hsp70.
- PAMP pathogen- associated molecular patterns
- CD 154 the ligand for CD40 (CD40L, gp39) is a 32-39 kD member of the Tumor
- Necrosis Factor Family which includes TNF- ⁇ , lymphotoxin, FasL, CD30L, CD27L, 4- IBBL, and OX-40L.
- Activated CD4 T ⁇ cells are the predominant cell type responsible for CD 154 expression. Expression of CDl 54 on CD8 + T-cells, eosinophils, mast cells and basophils, NK cells, and DCs has also been described.
- the receptor for CD 154, CD40 is a member of the tumor necrosis factor receptor (TNF-R) superfamily that includes TNF-RI ( ⁇ 55), TNF-RII (p75), p75 neurotrophin receptor, fas, CD30, CD27, 4- IBB, and OX-40.
- TNF-R tumor necrosis factor receptor
- CD 154 exerts far more profound effects on the early signaling, cytokine production and chemokine production compared to TNFIS and RANKL.
- One other critical impact of CD40 triggering of DCs is the change in the turnover of peptide-MHCII.
- CD40 agonists to elicit CMI in the absence of CD4 + T cells generated substantial enthusiasm to use CD40 agonists as adjuvants for cancer vaccines.
- a series of studies by Glennie and co-workers showed that one can achieve tumor regression of CD40 lymphoma using HCD40, but the doses of CD40 agonist were very high (250ug/day, days 2-5), and oddly, the tumor inoculum needed for immunization was very high (5xl0 7 /mouse). Nonetheless, clinical remission of these CD40 + lymphoma was impressive. Less impressive were studies on hematopoietic tumors which were CD40 " .
- CD40 + lymphomas and leukemias were due to direct effects of CD40 agonists on the tumor.
- GCD40 may also enhance their APC activities, and at the same time enhance their apoptosis.
- CD40 agonists could exert beneficial therapeutic effects on solid tumors. With solid tumors, a number of studies have shown that CD40 activation promotes apoptotic death and that CD40 expression is an important factor in the generation of tumor- specific T-cell responses that contribute to tumor cell elimination.
- CD40 agonists alone or TLR agonists alone could elicit effective therapeutic on Ad5El A expressing (CD40-) tumors in vivo (tumor type not described).
- TLR agonists Ad5El A expressing tumors in vivo (tumor type not described).
- Murphy and co-workers have shown that only the combination of an agonist CCD40 and IL-2, but neither agent administered alone, induced complete regression of metastatic tumor and specific immunity to subsequent rechallenge in the majority of treated mice. At this time efficacy with CD40 agonists alone is unpredictable.
- CD40 expression on the tumor is important, if tumor burden is important, if CD40 alone is adequate and if there is a distinctive difference in the efficacy of DCD40 therapy in liquid or solid tumors.
- CD40 agonists will induce high levels of tumor-specific immunity, and avoid the idiosyncrasies seen in different tumor models with DCD40 monotherapy.
- CD40 is a reasonable target for inducing heightened CMI responses for the purposes of tumor protection, yet the data in the literature suggested that it was not applicable in a wide range of tumors.
- My laboratory has worked intensively for a number of years to try to develop a general method to enhance protective tumor immunity using OCD40 as a monotherapy, and failed. Any and all parameters of dose of antibody, timing, route of inoculation, tumor type, different mabs, etc were extensively tested yet these efforts proved futile, except in B lymphoma and leukemia models, as reported by Glennie.
- Kedl and co-workers has shed much light on some of the important parameters that may influence the generation of protective CTL when using CD40 agonists.
- CD40 agonists Studies in both mouse and human have shown that the administration of CD40 agonists alone induce toxicity. In intact mice, it has been shown that CD40 agonists induce liver toxicity. In immune deficient mice and non-lethally-irradiated mice, the administration of CD40 agonists induce lethality. During the course of our studies with combined administration of DCD40 and TLR agonists (or IFNa) we discovered that the addition of either a TLR agonist or IFNa in vivo to mice treated with DCD40 resolved toxicity. Thus the co-administration of IFNa or TLR agonist with a CD40 agonist should resolve the toxicity observed in the clinical use of CD40 agonists.
- CD40 and TLR agonists in combination compared with either unitary adjuvant, elicit (1) high frequencies of self-reactive, effector CDS" T cells, (2) potent, tumor-specific CD8 + memory, (3) CD8 + T cells that efficiently infiltrate metastatic target organs and exert effector functions, (4) superior therapeutic efficacy, (5) heightened ratios of CD8 + T cells to FoxP3 + T cells at the tumor site, and (6) reduced hepatotoxicity.
- CD40 monoclonal antibodies have entered the clinic, (2, 4, 35) ⁇ i " B36 " ⁇ i "B37” - pg ⁇ Qn ⁇ Qne ⁇ ) o f w hi c h has been reported to be a strong agonist, similar to the antimurine CD40 used herein and in a wealth of other murine studies, for example. (39, 40) In that phase 1 study, 4 patients, each with stage IV melanoma, were found to have a partial response on restaging at the end of study.
- agonistic CD40 monotherapy While it may be premature to make any conclusive statements concerning agonistic CD40 monotherapy (2) as a vaccine platform, the preclinical studies in mice certainly suggest that it would be more effective as a vaccine when combined with activators of innate immunity. Even if not for clinical efficacy, the toxicity of CD40 monotherapy may be ameliorated with the addition of other immune activators.
- One indication where agonistic CD40 monotherapy may be suitable is in B-cell lymphoma where, in mice, high- dose monotherapy has been shown to be extremely effective (40, 41).
- Studies in animal models reveal that as unitary adjuvants, TLR agonists can elicit robust, inflammatory responses and enhance a wide spectrum of specific immune responses.
- TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol 2007; 178:1564-1572
- CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol 2007; 178:1662-1670.
- a modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model.
- J Immunol 2006; 177:155-161 [00233] 18.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08771163A EP2170931A4 (en) | 2007-06-15 | 2008-06-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
CN200880102354A CN101778861A (en) | 2007-06-15 | 2008-06-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
US12/664,921 US20110182847A1 (en) | 2007-06-15 | 2008-06-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
CA2691089A CA2691089A1 (en) | 2007-06-15 | 2008-06-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
AU2008265911A AU2008265911B2 (en) | 2007-06-15 | 2008-06-16 | Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens |
JP2010512421A JP2010530005A (en) | 2007-06-15 | 2008-06-16 | Use of a TLR agonist and / or type 1 interferon to alleviate the toxicity of a TNF-R agonist therapy regimen |
MX2009013779A MX2009013779A (en) | 2007-06-15 | 2008-06-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens. |
US13/863,460 US20130302278A1 (en) | 2007-06-15 | 2013-04-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94428807P | 2007-06-15 | 2007-06-15 | |
US60/944,288 | 2007-06-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/664,921 A-371-Of-International US20110182847A1 (en) | 2007-06-15 | 2008-06-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
US13/863,460 Continuation US20130302278A1 (en) | 2007-06-15 | 2013-04-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008157473A1 true WO2008157473A1 (en) | 2008-12-24 |
Family
ID=40156653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/067088 WO2008157473A1 (en) | 2007-06-15 | 2008-06-16 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
Country Status (9)
Country | Link |
---|---|
US (2) | US20110182847A1 (en) |
EP (1) | EP2170931A4 (en) |
JP (1) | JP2010530005A (en) |
KR (1) | KR20100034010A (en) |
CN (1) | CN101778861A (en) |
AU (1) | AU2008265911B2 (en) |
CA (1) | CA2691089A1 (en) |
MX (1) | MX2009013779A (en) |
WO (1) | WO2008157473A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150238582A1 (en) * | 2012-09-10 | 2015-08-27 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
US20170065692A1 (en) * | 2011-01-10 | 2017-03-09 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
US10202426B2 (en) | 2014-07-30 | 2019-02-12 | Genome Protection, Inc. | Flagellin compositions and uses |
WO2022117869A3 (en) * | 2020-12-04 | 2022-07-14 | Universiteit Antwerpen | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2821117C (en) | 2011-01-10 | 2019-02-12 | Ct Atlantic Ltd. | Combination therapy including tumor associated antigen binding antibodies |
TWI716362B (en) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | Antibody molecules to pd-l1 and uses thereof |
CA3061077A1 (en) * | 2016-04-26 | 2017-11-02 | Qu Biologics Inc. | Therapeutically triggering an innate immune response in a target tissue |
KR20230149857A (en) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Antibody adjuvant conjugates |
US20200087625A1 (en) * | 2017-03-30 | 2020-03-19 | Dennis A. Carson | Methods for isolating, expanding and administering cancer specific cd8+ t cells |
AR111651A1 (en) * | 2017-04-28 | 2019-08-07 | Novartis Ag | CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CN113827586B (en) * | 2021-09-06 | 2022-07-26 | 武汉市金银潭医院(武汉市传染病医院) | Application of nortriptyline hydrochloride in preparation of anti-enterovirus drugs |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040228877A1 (en) * | 2003-02-06 | 2004-11-18 | Dubensky Thomas W. | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
US20060188913A1 (en) * | 2001-10-12 | 2006-08-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US20070009480A1 (en) * | 2005-06-20 | 2007-01-11 | Villarete Lorelie H | Low-toxicity, long-circulating human interferon-alpha analogs |
US20070014807A1 (en) * | 2003-09-03 | 2007-01-18 | Maida Anthony E Iii | Multiplex vaccine |
US20070072202A1 (en) * | 2005-03-24 | 2007-03-29 | Bates Elizabeth E M | Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003300184B8 (en) * | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
JP5427027B2 (en) * | 2006-05-03 | 2014-02-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト | CD40 agonist antibody / type I interferon synergistic adjuvant conjugates, conjugates comprising the same, and their use as therapeutics to enhance cellular immunity |
CN101479375B (en) * | 2006-05-03 | 2016-03-30 | 科罗拉多州立大学董事会 | CD40 agonist antibody/type 1 interferon synergistic adjuvant combines, comprise the purposes of aforesaid binding substances and the therapeutical agent as enhancing cellular immunization thereof |
-
2008
- 2008-06-16 AU AU2008265911A patent/AU2008265911B2/en not_active Ceased
- 2008-06-16 US US12/664,921 patent/US20110182847A1/en not_active Abandoned
- 2008-06-16 CN CN200880102354A patent/CN101778861A/en active Pending
- 2008-06-16 WO PCT/US2008/067088 patent/WO2008157473A1/en active Application Filing
- 2008-06-16 EP EP08771163A patent/EP2170931A4/en not_active Withdrawn
- 2008-06-16 MX MX2009013779A patent/MX2009013779A/en active IP Right Grant
- 2008-06-16 KR KR1020107001008A patent/KR20100034010A/en not_active Application Discontinuation
- 2008-06-16 CA CA2691089A patent/CA2691089A1/en not_active Abandoned
- 2008-06-16 JP JP2010512421A patent/JP2010530005A/en active Pending
-
2013
- 2013-04-16 US US13/863,460 patent/US20130302278A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188913A1 (en) * | 2001-10-12 | 2006-08-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US20040228877A1 (en) * | 2003-02-06 | 2004-11-18 | Dubensky Thomas W. | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
US20070014807A1 (en) * | 2003-09-03 | 2007-01-18 | Maida Anthony E Iii | Multiplex vaccine |
US20070072202A1 (en) * | 2005-03-24 | 2007-03-29 | Bates Elizabeth E M | Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors |
US20070009480A1 (en) * | 2005-06-20 | 2007-01-11 | Villarete Lorelie H | Low-toxicity, long-circulating human interferon-alpha analogs |
Non-Patent Citations (4)
Title |
---|
GARAY ET AL.: "Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 563, no. 1-3, 1 June 2007 (2007-06-01), pages 1 - 17, XP022041836 * |
See also references of EP2170931A4 * |
SHEPHERD ET AL.: "Anti-CD40 Treatment of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-Exposed C57Bi/b Mice Induces Activation of Antigen Presenting Cells Yet Fails to Overcome TCDD-Induced Suppression of Allograft Immunity", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 170, 2001, pages 10 - 22, XP008130570 * |
VONDERHEIDE ET AL.: "Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 7, 1 March 2007 (2007-03-01), pages 876 - 883, XP008127182 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170065692A1 (en) * | 2011-01-10 | 2017-03-09 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
US10034926B2 (en) | 2011-01-10 | 2018-07-31 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
US11628201B2 (en) | 2011-01-10 | 2023-04-18 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
US10780152B2 (en) | 2011-01-10 | 2020-09-22 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
US10265390B2 (en) | 2011-01-10 | 2019-04-23 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
US20150238582A1 (en) * | 2012-09-10 | 2015-08-27 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
US10336793B2 (en) | 2014-07-30 | 2019-07-02 | Genome Protection, Inc. | Flagellin-based agents and uses including effective vaccination |
US10669316B2 (en) | 2014-07-30 | 2020-06-02 | Genome Protection, Inc. | Flagellin compositions and uses |
US10730915B2 (en) | 2014-07-30 | 2020-08-04 | Genome Protection, Inc. | Flagellin-based agents and uses including effective vaccination |
US10202426B2 (en) | 2014-07-30 | 2019-02-12 | Genome Protection, Inc. | Flagellin compositions and uses |
US10975127B2 (en) | 2014-07-30 | 2021-04-13 | Genome Protection, Inc. | Flagellin-based agents and uses including effective vaccination |
US11034733B2 (en) | 2014-07-30 | 2021-06-15 | Genome Protection, Inc. | Flagellin compositions and uses |
US11542306B2 (en) | 2014-07-30 | 2023-01-03 | Genome Protection, Inc. | Flagellin-based agents and uses including effective vaccination |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
WO2022117869A3 (en) * | 2020-12-04 | 2022-07-14 | Universiteit Antwerpen | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment |
Also Published As
Publication number | Publication date |
---|---|
CN101778861A (en) | 2010-07-14 |
AU2008265911B2 (en) | 2013-05-16 |
JP2010530005A (en) | 2010-09-02 |
KR20100034010A (en) | 2010-03-31 |
US20130302278A1 (en) | 2013-11-14 |
US20110182847A1 (en) | 2011-07-28 |
MX2009013779A (en) | 2010-05-20 |
AU2008265911A1 (en) | 2008-12-24 |
EP2170931A4 (en) | 2010-06-30 |
EP2170931A1 (en) | 2010-04-07 |
CA2691089A1 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008265911B2 (en) | Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens | |
US20200087370A1 (en) | Cd40 agonist antibody /type 1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity | |
JP2011026328A (en) | Oligonucleotide composition and use thereof for modulation of immune response | |
TW200911274A (en) | Alpha-galatosyl ceramide analogs and their use as immunotherapies | |
WO2007103048A2 (en) | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity | |
US10463731B2 (en) | Adjuvant combinations comprising alpha-galactosylceramide or iGb3, CD40 agonists and antigen | |
WO2002036141A2 (en) | Method of enhancing lymphocyte-mediated immune responses | |
JP5745577B2 (en) | CD40 agonist antibody / type I interferon synergistic adjuvant conjugates, conjugates comprising the same, and their use as therapeutics to enhance cellular immunity | |
JP4836957B2 (en) | Combination of recombinant mycobacterium and biologically active agent as a vaccine | |
JP2005528373A (en) | Method using Flt3 ligand in immunization protocol | |
JP7271433B2 (en) | Immunostimulants, immunotherapeutic pharmaceutical compositions, and their preparation and use | |
EP2992898A1 (en) | T-cell adjuvant and its use for therapeutic or prophylactic vaccination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880102354.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08771163 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2691089 Country of ref document: CA Ref document number: 2010512421 Country of ref document: JP Ref document number: MX/A/2009/013779 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008265911 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4466/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008771163 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107001008 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2008265911 Country of ref document: AU Date of ref document: 20080616 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12664921 Country of ref document: US |